Redeye comments on BioInvent's fourth-quarter report 2024. The main event occurred in January 2025 with an anticipated important readout of BI-1808 monotherapy and BI-1206 triplet, which contained little new information on BI-1808 and just two patients for BI-1206, leading to a share price retreat. Nonetheless, BI-1808 and BI-1206 are on schedule for major readouts in mid-2025 with deal-making potential. We estimate a new base case.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/